Closing Medicine's Gender Gap

For decades, medical research has treated men as the default human body. The consequences of that decision have shaped everything from how diseases are diagnosed to how medications are prescribed. Although women make up roughly half the population, they have historically been excluded from many clinical trials, especially during the second half of the twentieth century. Researchers often argued that hormonal fluctuations made women "too complicated" to study, while fears surrounding pregnancy risks after the thalidomide tragedy of the 1960s led regulators to become even more restrictive. In 1977, the U.S. Food and Drug Administration (FDA) formally recommended excluding women of childbearing age from early-stage drug trials, a policy that still reverberates today.

The long-term effects of this exclusion are increasingly visible. Many medications were originally tested primarily on men - despite evidence that women metabolize drugs differently, experience different side effects, and may display entirely different symptoms for the same illnesses. One recent analysis noted that fewer than 30% of participants in industry-sponsored early-phase trials were women. Even when women are included in studies, gender-specific analysis is often limited, meaning researchers may not fully investigate how outcomes differ between men and women.

London Epidemiologist Dr. Amy Brenner recently warned that this underrepresentation creates "a lack of evidence on the safety and effectiveness of many interventions in women." A 2024 review in the medical literature stated that women's symptoms and disease progression have often been misunderstood because medical studies historically focused on men. Cardiologist Dr. Christopher Le explained that "we know less about women because we haven't studied them as long." That gap in knowledge affects heart disease, autoimmune disorders, chronic pain, Alzheimer's disease, osteoporosis, and even conditions like ADHD and autism, which are frequently diagnosed later in women because diagnostic standards were originally developed around male patients.

The gender gap in medical research is maybe most obviously seen in cardiovascular medicine. Even though it remains one of the leading causes of death for women, heart disease has long been perceived as a predominantly male issue. Historically, "classic" heart attack symptoms were defined using male-centered data, emphasizing crushing chest pain and pain radiating down the left arm. Women, however, are more likely to experience symptoms such as nausea, jaw pain, fatigue, dizziness, or shortness of breath. Because their symptoms did not fit the traditional research model, women's cardiac events have often been overlooked or misdiagnosed. The British Heart Foundation reported that women are 50% more likely than men to receive an incorrect initial diagnosis after a heart attack, and further research found that women under the age of 55 were seven times more likely than men to be sent home from emergency rooms without proper cardiac testing.

Pain management represents another major area where the gender gap has had measurable consequences. Numerous studies have shown that women's pain is more likely to be dismissed as emotional or psychological. Researchers have documented that women reporting severe pain are often perceived as exaggerating symptoms or being anxious, while men reporting the same symptoms are more likely to receive immediate testing and aggressive treatment. This disparity can delay diagnoses for serious conditions and chronic illnesses for years. In some cases, women spend nearly a decade seeking answers before receiving an accurate diagnosis. The result is not simply frustration but worsening health outcomes and higher healthcare costs over time.

Despite the persistence of the problem, progress has been made over the past several decades. In 1993, the National Institutes of Health (NIH) Revitalization Act officially required women and minorities to be included in NIH-funded clinical research. Since then, federal agencies and medical institutions have increasingly pushed for sex-based data analysis in studies. Medical schools have also begun placing greater emphasis on gender-specific medicine and recognizing how diseases can present differently across populations.

The broader issue is that medicine has long presented itself as objective while relying on incomplete data. When half of the population is insufficiently represented in medical research, the entire healthcare system becomes skewed. Diagnostic standards, treatment guidelines, pharmaceutical dosages, and medical education inherit those biases. As awareness grows, researchers and physicians are increasingly acknowledging that studying women's health separately is essential to building a healthcare system that works for everyone.